1. Academic Validation
  2. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response

The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response

  • EMBO Rep. 2008 Sep;9(9):930-6. doi: 10.1038/embor.2008.136.
Constantin S Friedman 1 Marie Anne O'Donnell Diana Legarda-Addison Aylwin Ng Washington B Cárdenas Jacob S Yount Thomas M Moran Christopher F Basler Akihiko Komuro Curt M Horvath Ramnik Xavier Adrian T Ting
Affiliations

Affiliation

  • 1 Immunology Institute, Mount Sinai School of Medicine, Box 1630, One Gustave L Levy Place, New York, New York 10029, USA.
Abstract

On detecting viral RNAs, the RNA helicase retinoic acid-inducible gene I (RIG-I) activates the interferon regulatory factor 3 (IRF3) signalling pathway to induce type I interferon (IFN) gene transcription. How this Antiviral signalling pathway might be negatively regulated is poorly understood. Microarray and bioinformatic analysis indicated that the expression of RIG-I and that of the tumour suppressor CYLD (cylindromatosis), a deubiquitinating Enzyme that removes Lys 63-linked polyubiquitin chains, are closely correlated, suggesting a functional association between the two molecules. Ectopic expression of CYLD inhibits the IRF3 signalling pathway and IFN production triggered by RIG-I; conversely, CYLD knockdown enhances the response. CYLD removes polyubiquitin chains from RIG-I as well as from TANK binding kinase 1 (TBK1), the kinase that phosphorylates IRF3, coincident with an inhibition of the IRF3 signalling pathway. Furthermore, CYLD protein level is reduced in the presence of tumour necrosis factor and viral Infection, concomitant with enhanced IFN production. These findings show that CYLD is a negative regulator of RIG-I-mediated innate Antiviral response.

Figures